pharma news

Sep 09, 2021

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 Billion A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indic...

Sep 07, 2021

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials  As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a critical late-stage study of its experimental vaccine against a severe version of a cold virus that may cause pneumonia ...

Aug 31, 2021

FDA's Green Flag to Ascendis's Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone Deficiency For the treatment of growth failure due to deficiency of growth hormones, the USFDA approved Ascendis Pharma's Skytrofa (lonapegsomatropin-tcgd) for children of one year and older suffering from an improper s...

Aug 26, 2021

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technol...

Aug 24, 2021

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca's 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neu...

Aug 17, 2021

FDA’s Green Flag to Keytruda and Lenvima combination by Merck and Eisai for Advanced renal cell carcinoma (RCC) The FDA approved the combination of Keytruda and Lenvima produced by Merck and Eisai, as a first-line treatment of adult patients with advanced renal cell carcinoma (RCC). The efficacy and safety resul...

Aug 12, 2021

LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with USD 19 million.  The two-year-old Canadian biotech will utiliz...

Aug 10, 2021

FDA Approves Keytruda in Both Adjuvant and Neoadjuvant Setting in High-Risk Early-Stage TNBC In July 2021, the US FDA approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as...

Aug 05, 2021

Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acq...

Jul 29, 2021

Teneobio and its next-gen cancer work acquired by Amgen  Amgen has penned a major new buyout deal to boost its oncology pipeline further. The biopharma is putting USD 900 million down upfront, with USD 1.6 billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibod...